2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one BUPROPION BUPROPION HYDROCHLORIDE BDBM50048392 CHEMBL894 US9944618, Compound ID No. 176
BW-323 Bupropion Wellbutrin CHEMBL1698 Wellbutrin xl BUPROPION HYDROCHLORIDE 2-tert-Butylamino-1-(3-chloro-phenyl)-propan-1-one; hydrochloride Zyban Amfebutamone Hydrochloride Wellbutrin sr BDBM50290504
- Carroll, FI; Blough, BE; Abraham, P; Mills, AC; Holleman, JA; Wolckenhauer, SA; Decker, AM; Landavazo, A; McElroy, KT; Navarro, HA; Gatch, MB; Forster, MJ Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem 52: 6768-81 (2009)
- Carroll, FI; Blough, BE; Mascarella, SW; Navarro, HA; Eaton, JB; Lukas, RJ; Damaj, MI Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem 53: 2204-14 (2010)
- Lapinsky, DJ; Aggarwal, S; Nolan, TL; Surratt, CK; Lever, JR; Acharya, R; Vaughan, RA; Pandhare, A; Blanton, MP (±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban). Bioorg Med Chem Lett 22: 523-6 (2011)
- ChEMBL_1435701 Inhibition of CYP2B6 (unknown origin) using bupropion substrate
- ChEMBL_1487656 Reversible inhibition of human CYP2B6 bupropion hydroxylase activity
- ChEMBL_1667012 Inhibition of human liver microsomes CYP2B6 using bupropion as substrate
- ChEMBL_2100788 Direct inhibition of CYP2B6 in human liver microsomes using bupropion as substrate
- ChEMBL_690369 Inhibition of CYP2B6 in human liver microsomes using bupropion as probe after 10 mins
- ChEMBL_854492 Inhibition of human CYP2B6 in liver microsomes assessed as bupropion hydroxylation after 48 hrs
- ChEMBL_2110154 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate by LC-MS/MS analysis
- ChEMBL_2156136 Inhibition of CYP2B6 in human liver microsomes using Bupropion as substrate by LC-MS/MS analysis
- ChEMBL_690366 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion 4-hydroxylation after 10 mins
- ChEMBL_1526169 Reversible inhibition of CYP2B6 bupropion hydroxylase activity in human liver microsomes by LC-MS/MS analysis
- ChEMBL_2100798 Time-dependent inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 30 mins
- ChEMBL_738480 Mechanism based inhibition of human cytochrome P450 2B6 measured by bupropion hydroxylation using recombinant CYP2B6
- ChEMBL_738482 Mechanism based inhibition of human cytochrome P450 2B6 measured by bupropion hydroxylation using a recombinant system
- ChEMBL_738479 Mechanism based inhibition of human cytochrome P450 2B6 measured by bupropion hydroxylation using human liver microsomes
- ChEMBL_738481 Mechanism based inhibition of human cytochrome P450 2B6 measured by bupropion hydroxylation using human liver microsomes
- ChEMBL_977235 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation after 20 mins by LC-MS analysis
- ChEMBL_1281749 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation after 20 mins by LC-MS/MS analysis
- ChEMBL_2066469 Inhibition of human liver microsome CYP2B6 using bupropion as substrate incubated for 20 mins by LC-MS/MS analysis
- ChEMBL_2101772 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate substrate in presence of NADPH by LC-MS/MS analysis
- ChEMBL_690376 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion 4-hydroxylation after 15 mins by Dixon plot analysis
- ChEMBL_813099 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 5 mins by LC-MS/MS analysis
- ChEMBL_1486257 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate after 5 to 30 mins by LC-MS/MS analysis
- ChEMBL_1904191 Inhibition of CYP2B6 in human pooled liver microsomes using bupropion as substrate after 10 mins by UPLC-MS/MS analysis
- ChEMBL_1492463 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH
- ChEMBL_1492473 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH
- ChEMBL_1742655 Inhibition of of CYP2B6 in human liver microsomes using bupropion as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis
- ChEMBL_1904557 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis
- ChEMBL_1992477 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate incubated for 20 mins in presence of NADPH by LC/MS/MS analysis
- ChEBML_1661006 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 10 mins followed by NADPH addition measured after 20 mins
- ChEMBL_1481819 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis
- ChEMBL_1658364 Inhibition of microsomal CYP2B6 (unknown origin) using bupropion as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis
- ChEMBL_1661006 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 10 mins followed by NADPH addition measured after 20 mins
- ChEMBL_2025182 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis
- ChEMBL_2101710 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis
- ChEMBL_2124310 Inhibition of CYP2B6 in human liver microsomes assessed as bupropion hydroxylation reaction incubated for 30 mins in presence of NADP by LC-MS/MS analysis
- ChEMBL_1661000 Inhibition of human CYP2B6 using bupropion as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis
- ChEMBL_1677529 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate upto 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis
- ChEMBL_1493635 Metabolism-dependent inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis
- ChEMBL_1764604 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate pretreated for 5 mins followed by NADPH addition and measured after 10 mins by LC-MS analysis
- ChEMBL_1845025 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 5 mins followed by NADPH addition and measured for 10 to 30 mins by LC-MS/MS analysis
- ChEMBL_1902235 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 5 mins followed by NADPH addition and measured for 10 to 30 mins by LC-MS/MS analysis
- ChEMBL_1735366 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis
- ChEMBL_1660956 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins in presence of NADPH by LC-MS/MS analysis
- ChEMBL_1805640 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis
- ChEMBL_1904194 Inhibition of CYP2B6 in human pooled liver microsomes using bupropion as substrate preincubated with NADPH for 30 mins followed by substrate addition and measured after 10 mins by UPLC-MS/MS analysis
- ChEMBL_2080678 Inhibition of CYP2B6 in human liver microsomes using bupropion as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis
- ChEMBL_1660893 Inhibition of CYP2B6 in human liver microsomes assessed as enzyme-mediated metabolite formation using bupropion as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis
- Inhibition Assay Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.3%) are incubated with human liver microsomes (0.1 mg/mL) and NADPH (1 mM) in the presence of the probe substrate bupropion (110 μM) for 5 min at 37° C. The selective CYP2B6 inhibitor, ticlopidine, is screened alongside the test compounds as a positive control.
- CYP450 Inhibition Assay The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.